網膜静脈閉塞症に伴う黄斑浮腫に対するラニビズマブの短期成績

Short-term outcome of intravitreal ranibizumab for retinal vein occlusion with macular edema

要約　目的：網膜静脈閉塞症に伴う黄斑浮腫に対するラニビズマブ硝子体注射の短期成績の報告。対象と方法：網膜静脈閉塞症22例22眼を対象とした。男性10例，女性12例で，年齢は44〜83歳，平均70歳であった。網膜中心動脈閉塞症が5眼，網膜静脈分枝閉塞症が17眼にあった。併発した黄斑浮腫に対してラニビズマブ硝子体注射を行い，6か月間の経過を観察した。必要に応じてラニビズマブ投与を追加した。視力はlogMARで評価した。結果：経過中に平均2.4回のラニビズマブ追加投与を行った。平均視力は投与前0.64±0.41，6か月後は0.56±0.50で，改善傾向を示した。中心窩網膜厚は，治療前には平均577.8±207.0μm，治療の翌日が459.0±144.6μm，6か月後が373.1±102.9μmであり，有意に減少した。結論：網膜静脈閉塞症に伴う黄斑浮腫に対するラニビズマブ硝子体注射で，その翌日から黄斑浮腫が減少し，短期的な視力の改善が得られた。

Abstract.　Purpose：To report a 6-month outcome of intravitreal injection of ranibizumab for retinal vein occlusion with macular edema. Cases and Method：This retrospective study was made on 22 eyes of 22 cases with retinal vein occlusion. The series comprised 10 males and 12 females. The age ranged from 44 to 83 years, average 70 years. Central retinal vein occlusion was present in 5 eyes and branch retinal vein occlusion in 17 eyes. Cases were followed up for 6 months after ranibizumab injection. The treatment was repeated when needed. Visual acuity was evaluated in terms of logMAR. Results：Ranibizumab injection was repeated 2.4 times during 6 months. Visual acuity averaged 0.64±0.41 before treatment and 0.56±0.50 after 6 months. Central foveal thickness averaged 577.8±207.0μm before treatment, 459.0±144.6μm the following day, and 373.1±102.9μm after 6 months. The differences were significant. Conclusion：Intravitreal injection of ranibizumab was followed by decrease of macular edema on the following day and by short-term improvement of visual acuity.